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Abstract It has been suggested that the concentrations of
tamoxifen and its demethylated metabolites increase with
age. We measured the serum concentrations of the active
tamoxifen metabolites, 4OHtamoxifen (4OHtam), 4-
hydroxy-N-desmethyltamoxifen (4OHNDtam, Endoxifen),
tamoxifen and its demethylated metabolites. Their relations
to age were examined. One hundred fifty-one estrogen
receptor and/or progesterone receptor positive breast cancer
patients were included. Their median (range) age was 57
(32–85) years. Due to the long half-life of tamoxifen, only
patients treated with tamoxifen for at least 80 days were
included in the study in order to insure that the patients had
reached steady-state drug levels. Tamoxifen and its metab-
olites were measured by liquid chromatography-tandem
mass spectrometry. Their serum concentrations were related
to the age of the patients. To circumvent effects of cyto-
chrome (CYP) 2D6 polymorphisms we also examined these
correlations exclusively in homozygous extensive
metabolizers. The concentrations of 4OHNDtam, tamoxifen,
NDtam (N-desmethyltamoxifen), and NDDtam (N-desdim-
ethyltamoxifen) were positively correlated to age (n = 151,
p = 0.017, 0.045, 0.011, and 0.001 respectively). When
exclusively studying the CYP2D6 homozygous extensive
metabolizers (n = 86) the correlation between 4OHNDtam
and age increased (p = 0.008). Up to tenfold inter-patient
variation in the serum concentrations was observed. The
median (inter-patient range) concentration of 4OHNDtam in
the age groups 30–49, 50–69, and [69 years were 65
(24–89), 116 (25–141), and 159 (26–185) ng/ml, respec-
tively. We conclude that the serum concentrations of
4OHNDtam (endoxifen), tamoxifen, and its demethylated
metabolites increase with age during steady-state tamoxifen
treatment. This may represent an additional explanation why
studies on the effects of CYP2D6 polymorphisms on out-
come in tamoxifen-treated breast cancer patients have been
inconsistent. The observed high inter-patient range in serum
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concentrations of tamoxifen and its metabolites, especially
in the highest age group, suggest that use of therapeutic
monitoring of tamoxifen and its metabolites is warranted.













The selective estrogen receptor modulator (SERM)
tamoxifen is used in the treatment of breast cancer patients
with estrogen receptor positive (ER?) tumors. It is the gold
standard in adjuvant endocrine therapy for premenopausal
women and may also be used as a preventive agent in
premenopausal as well as postmenopausal women with a
high risk of breast cancer.
Tamoxifen acts as an estrogen antagonist or agonist
depending on tissue type [1] which may be due to variation
of ER co-activators and inhibitors in tissues. The agonistic
effects of tamoxifen are associated with favorable effects,
such as prevention of bone fractures, but also some rare,
serious detrimental effects may occur, including endome-
trial cancer and venous thromboembolic events. Further-
more, adverse effects like hot flushes and vaginal discharge
are often observed [2, 3]. Used adjuvantly a compliance of
only 50 % has been observed after 5 years treatment [4–6].
The anticancer effect of tamoxifen is believed to be due to
the hydroxylated metabolites, 4-hydroxytamoxifen (4OH-
tam), and 4-hydroxy-N-desmethyltamoxifen (4OHNDtam/
endoxifen), because of their high affinity for the ER [7, 8],
whereas the demethylated metabolites of tamoxifen have been
associated with its side effects [9]. As 4OHNDtam is present in
blood in concentrations about ten times higher than 4OHtam it
is supposed to be the most important metabolite [10]. Multiple
enzymes are involved in activation and inactivation of
tamoxifen. Some of these enzymes are polymorphic, including
CYP2D6, CYP2C19, CYP3A4 sulfotransferase (SULT),
Uridine 50-diphospho-glucuronosyltransferase (UGT) [11–
14], and other drugs may modulate their activity [15–18] .
Multiple factors including drug interactions [15–18],
genetic polymorphisms of tamoxifen metabolizing
enzymes [10, 18–20], and seasonal variation [21] influence
the pharmacokinetics of tamoxifen. Effects of these factors
may explain inconsistent results from clinical studies
linking genetic polymorphisms of these enzymes to clinical
outcome during tamoxifen treatment [22–25].
In the present study we analysed serum samples from
breast cancer patients obtained during steady-state tamox-
ifen treatment and observed that the serum levels of
tamoxifen and its metabolites increase with age. Further-
more, the inter-patient range of serum concentrations was
up tenfold and highest in the oldest age group. The results
suggest that tamoxifen treatment may be improved by
means of therapeutic drug monitoring.
Materials and methods
Study population
The study protocol and the main results have been
described in detail elsewhere [10]. From October 2002 to
October 2003, Caucasian women with breast cancer were
consecutively recruited from Haukeland University Hos-
pital, St Olav University Hospital and Førde Central Hos-
pital in Norway. All patients were ER and/or PR positive.
Written informed consent was obtained from each patient.
The protocol was approved by the National Committee for
Medical and Health Research Ethics (NEM). Due to the
long half-life of tamoxifen, only patients treated with
20 mg tamoxifen adjuvant per day for more than 80 days
were included in the study in order to insure that patients
had reached steady-state drug levels. Postmenopausal sta-
tus was defined as FSH levels[20 IU/L and estradiol (E2)
levels\70 pmol/L, using the automated analyzer Immulite
2000 (Diagnostic Products Corporation, Los Angeles, CA).
When only one of these criteria was fulfilled, the patients
were defined as perimenopausal.
Determination of tamoxifen and its metabolites
concentrations in serum
We used a high-pressure liquid chromatography–tandem
mass spectrometry system that was developed for the
determination of tamoxifen and its metabolites in serum
[10, 26]. The assay was modified to improve the sensitivity
by changing the API 2000/Qtrap mass spectrometry system
from Applied Biosystems (AB MDS Sciex, Concord,
Canada) to the API 4000, equipped with TurboIonSpray.
CYPD6 genotype determination
Genomic leukocyte DNA was extracted from EDTA anti-
coagulated whole blood using the QIAamp DNA Blood Mini
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Kit (Qiagen, Hilden, Germany). The CYP2D6 genotypes
were tested previously and subdivided into four groups and
ranked according to their predicted increasing enzymatic
activity: poor metaboliser [subjects with any combination of
two non-functional variant type (Vt) alleles *3, *4, *5, and
*6], intermediate metabolizer [heterozygous; wild type/
variant type], wild type/wild-type (Wt/Wt) extensive me-
tabolizer (EM) CYP2D6, and ultra-rapid metabolizer [het-
erozygous; Vt allele *2 9 2/wild type] [10].
Statistical analysis
Two-tailed Spearman correlation rank tests were used to
examine the correlations between tamoxifen and metabo-
lite concentrations in serum and breast cancer tissues.
p \ 0.05 was considered statistically significant. The
Kruskal–Wallis test was used to compare samples from
different age groups. All p values were two-sided. Statis-
tical analyses were performed with IBM SPSS Statistics
software, version 19 (SPSS Inc, Chicago, Illinois).
Results
One hundred fifty-one breast cancer patients were included
in the study. The median (range) age of the patients was 57
(32–85) years. Fifteen of the patients were premenopausal,
17 perimenopausal, and 119 postmenopausal. We observed
a more than tenfold inter-patient variation in serum con-
centrations of tamoxifen and some of its metabolites
(Table 1). The concentrations of tamoxifen, 4OHNDtam,
and NDDtam were positively correlated to age (Table 1).
The number of poor, intermediate, extensive, and ultra-
rapid metabolizers were 11, 49, 86, and 5, respectively.
The overall CYP2D6 genotype distribution was in accor-
dance with an expected Hardy–Weinberg equilibrium.
To circumvent effects of CYP2D6 polymorphisms we
also studied these correlations exclusively in EMs. Although
the number of patients included in this calculation was
reduced from 151 to 86, the positive correlation between
4OHNDtam and age increased and the p value improved
(Table 1). In the total subgroup of postmenopausal women
(n = 119) the relationship between 4OHNDtam and age was
not significant (p = 0.107, correlation coefficient 0.148).
However, in the subgroup of CYP2D6 extensive metabo-
lizers (n = 69), the correlation was highly significant (p =
0.007, correlation coefficient 0.322) (Fig. 1).
When analyzing the premenopausal subgroup sepa-
rately, the serum concentrations of tamoxifen and its
metabolites were not related to age (data not shown),
possibly due to the low number of premenopausal patients
(n = 15). However, a trend was observed for 4OHNDtam
(p = 0.053). We also examined the median and range of the
serum concentrations in the age groups 30–49 years,
50–69 years, and [69 years separately (Table 2). There
was an up to tenfold inter-patient variation in the serum
concentrations, and the inter-patient range increased with
age. The Kruskal–Wallis test showed statistical differences
in the serum levels of tamoxifen, 4OHtam, NDtam, and
NDDtam between the age groups of 30–49, 50–69, and
[69 years (data not shown).
Discussion
We observed in the present study that the serum concen-
trations of the active tamoxifen metabolite, 4OHNDtam
(endoxifen), increase with age during steady-state tamox-
ifen treatment. Our findings are in line with a study pub-
lished earlier this year by Teft et al. [21]. Peyrade et al. [27]
and Sheth et al. [28] have previously observed that the
serum concentrations of tamoxifen and its demethylated
metabolites increased significantly with age.
Another important finding is that the high inter-patient
variation in serum concentrations of 4OHNDtam was most
pronounced in the oldest patient group, probably due to
Table 1 Serum concentrations of tamoxifen and its metabolites correlate with age
Tamoxifen 4OHtama 4OHNDtam NDtam NDDtam TamNox
Serum concentrations (ng/ml)b
All (n = 151) 89.9 (27.1–302.1) 5.7 (1.7–17.2) 49.6 (24.3–184.8) 225.7 (90.1–690.9) 37.0 (11.4–93.4) 9.4 (2.7–37.9)
Wt/Wt EM (n = 86) 90.5 (33.9–291.1) 5.8 (2.2–17.2) 52.3 (24.3–184.8) 216.7 (90.1–596.3) 37.7 (11.4–93.4) 9.0 (3.2–29.0)
Correlations with age (R(p))c
All (n = 151) 0.163 (0.045) 0.120 (0.141) 0.195 (0.017)) 0.207 (0.011) 0.260 (0.001) 0.112 (0.172)
Wt/Wt EM (n = 86) 0.203 (0.060) 0.190 (0.080) 0.285 (0.008) 0.250 (0.020) 0.263 (0.014) 0.191 (0.079)
a 4OHtam 4-hydroxytamoxifen, 4OHNDtam 4-hydroxy-N-demethyltamoxifen, NDtam N-demethyltamoxifen, NDDtam N-dedimethyltamoxi-
fen, tamNox tamoxifen-N-oxide, Wt/Wt EM wild type/wild type extensive metabolizer CYP2D6
b Median (range)
c R and p values are derived from two-tailed Spearman correlation rank test
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more concomitant diseases and increased use of additional
drugs that may interact with tamoxifen metabolism. As
creatinine clearance declines gradually with age and uri-
nary elimination represents a major excretory route for
4OHNDtam [29], this may also cause higher 4OHNDtam
levels in older patients [30]. The observation of higher
4OHNDtam levels and a high inter-patient variation of
4OHNDtam in the oldest patient group may in part explane
the inconsistencies between studies linking CYP2D6
polymorphisms to outcome. This may further explain the
finding of Margolin et al. [31] that the effect of CYP2D6
seems to derive mainly from premenopausal patients.
Tamoxifen dosage is based on the one-dose-fits-all
approach. The up to tenfold variation in serum and tissue
concentrations of tamoxifen and its metabolites [10, 32],
which have been observed in multiple clinical studies, may
influence the outcome and occurrence of adverse effects. It
is still not sufficiently defined which concentrations are
needed for optimal effects and at which concentrations side
effects develop. Decensi et al. [33] observed in a preop-
erative study, using 1, 5, or 20 mg tamoxifen daily for
4 weeks, that the expression of the tumor proliferation
marker Ki-67 decreased to the same extent irrespective of
dose. In line with this, Moi et al. [34] observed in tumor
tissues that an increase of coactivator mRNA levels seems
to be an early response to tamoxifen without dose–response
relationship in the 1- to 20-mg range.
Madlensky et al. [35] identified a threshold for the
serum concentrations of 4OHNDtam suggesting that the
women in the upper four quintiles of 4OHNDtam con-
centrations had a lower recurrence rate than women in the
bottom quintile. Furthermore, Love et al. [36] suggested a
J-shaped relationship between 4OHNDtam concentrations
in individual patients and likelihood of recurrence. Quite
recently, Gong et al. [37] using human MCF7 xenografts in
athymic nu/nu mice observed a relationship between en-
doxifen concentrations and tumor growth inhibition.
Side effects of tamoxifen seem to be related to the serum
levels of tamoxifen and its metabolites [38, 39]. Two
studies report that the proportion of tamoxifen and its
demethylated metabolites in serum was higher in patients
with toxicity versus those not experiencing toxicity [9, 27].
In order to increase the serum level of 4OHNDtam in
patients with decreased CYP2D6 activity, Kiyotani et al.
[40] increased the daily doses of tamoxifen from 20 to 30
or 40 mg for at least 8 weeks, with no increase of side
effects except from hyperhidrosis. Furthermore, some side
effects like endometrial carcinoma and retina disease
usually appear after long-term treatment and may be rela-
ted to the cumulative dose [40]. Thus, we need more
studies to better define the therapeutic range of 4OHNDtam
serum levels. Are the high levels of tamoxifen and its
metabolites in postmenopausal women of any clinical rel-
evance after the advent of aromatase inhibitors?
Tamoxifen may still be a first line drug in the adjuvant
treatment to some groups of postmenopausal women and
could certainly be used in the last 3 years of the 5-year
endocrine treatment period. In a recent study where 90 %
of the patients included were postmenopausal, it was
observed that prolonged tamoxifen treatment from 5 to
10 years halved breast cancer mortality during the second
decade after diagnosis [41]. In the BIG 1-98 randomized






















Fig. 1 Serum levels of 4OHNDtam and age in postmenopausal
patients with wt/wt CYP2D6 alleles (EM)
Table 2 Tamoxifen and metabolite concentrations in different age groups
Age (years) Tamoxifen 4OHtam 4OHNDtam NDtam NDDtam TamNox
30–49 (n = 33)
Median (ng/ml) 75 5.5 44 187 26 7.8
Range (min–max) 176 (27–203) 9.5 (1.7–11.3) 65 (24–89) 473 (90–563) 77 (11–89) 19 (2.7–21.2)
50–69 (n = 83)
Median (ng/ml) 95 5.8 51 229 38 9.5
Range (min–max) 271 (31–302) 10 (2.8–13.0) 116 (25–141) 575 (116–691) 78 (16–93) 34 (3.5–38.0)
[69 (n = 35)
Median (ng/ml) 96 5.5 54 255 42 10
Range (min–max) 188 (36–224) 15 (2.2–17) 159 (26–185) 415 (97–512) 72 (18–90) 21 (3.9–25)
246 Breast Cancer Res Treat (2013) 141:243–248
123
low risk [42]. In this group the overall survival favored
tamoxifen, although insignificantly, compared with treat-
ment with the aromatase inhibitor letrozole. Moreover,
osteoporosis and bone fractures were increased with le-
trozole compared to tamoxifen mono-therapy.
Tamoxifen treatment may be further improved by dose
adjustment based on direct measurement of the active
tamoxifen metabolites. Moreover, direct blood measure-
ments may help to detect low compliance, which is a
problem at least outside clinical studies [43]. Common
criteria for therapeutic drug monitoring are fulfilled for
tamoxifen, such as major inter-individual variation in
metabolism, difficulties in observing toxicity clinically,
and possibility of interactions and problems related to
compliance.
In summary, we observed that the serum concentrations
of 4OHNDtam (endoxifen) in breast cancer patients
increase with age during steady-state tamoxifen treatment.
The observed high inter-patient range in serum concen-
trations of tamoxifen and its metabolites, especially in the
highest age group, suggest that use of therapeutic moni-
toring of tamoxifen and its metabolites is warranted inside
as well as outside clinical studies.
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